Identification of the Major Degradation Pathways of Selumetinib

Selumetinib is administered orally in capsule form and is indicated for the treatment of neurofibromatosis. To facilitate dosage adjustments, liquid preparations, such as solutions or suspensions, are to be developed. This led, first, to determine the stability profile of soluble or dispersed selume...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchema, Tahar Sif eddine, Annereau, Maxime, Vieillard, Victoire, Boquet, Raphael, Coelho, Gisele Abreu, Castelli, Florence, Solgadi, Audrey, Paul, Muriel, Yagoubi, Najet, Secretan, Philippe-Henri, Do, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787286/
https://www.ncbi.nlm.nih.gov/pubmed/36559146
http://dx.doi.org/10.3390/pharmaceutics14122651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787286/
https://www.ncbi.nlm.nih.gov/pubmed/36559146
http://dx.doi.org/10.3390/pharmaceutics14122651

Ejemplares similares